Systematized linear porokeratosis: A rare variant of diffuse porokeratosis with good response to systemic acitretin

Hong, Jin‐Bon; Hsiao, Cheng–Hsiang; Chu, Chia-Yu

doi:10.1016/j.jaad.2008.10.011

Cited by 27 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, systemic retinoids were anecdotally used for diffuse porokeratosis. 1 Our patient declined etretinate, the only internal retinoid available in Japan. …”

mentioning

confidence: 76%

Unilateral generalized linear porokeratosis with nail dystrophy

Kono

Yokoyama

Ogawa

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

“…Therefore, systemic retinoids were anecdotally used for diffuse porokeratosis. 1 Our patient declined etretinate, the only internal retinoid available in Japan. …”

mentioning

confidence: 76%

Unilateral generalized linear porokeratosis with nail dystrophy

Kono

Yokoyama

Ogawa

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

“…Buna ra¤men malinite geliflme riski nedeniyle tedavi edilmeleri önerilmektedir 3 . Porokeratozlar›n tedavisinde topikal 5-florourasil, kalsipotriol, imikimod, kriyoterapi, dermabrazyon, elektrodesikasyon, CO2 lazer, 585-nm pulsed dye lazer, Nd:YAG lazer, sistemik olarak oral isotretinoin ve asitretin kullan›lmaktad›r 9 . Asitretin etretinat›n aktif metaboliti olan ikinci jenerasyon monoaromatik retinoidtir.…”

Section: Tart›flmaunclassified

“…Asitretin etretinat›n aktif metaboliti olan ikinci jenerasyon monoaromatik retinoidtir. Porokeratozdaki etki mekanizmas› tam olarak bilinmemekle beraber çeflitli keratinizasyon hastal›klar›nda epidermal hücre-lerin yenilenme h›z›n› azaltarak etkili oldu¤u düflünülmektedir 9 . Ayr›ca oral retinoidlerin kullan›m›n›n, özellikle immünsüprese hastalarda daha fazla olan deri malinitelerinin oluflma riskini azaltt›¤› bildirilmifltir 1 .…”

Section: Tart›flmaunclassified

“…Ayr›ca oral retinoidlerin kullan›m›n›n, özellikle immünsüprese hastalarda daha fazla olan deri malinitelerinin oluflma riskini azaltt›¤› bildirilmifltir 1 . Literatürde özellikle etretinat ile baflar› sa¤lanm›fl porokeratoz vakalar›na rastlanm›flt›r 9,10,11 . Hong ve ark.…”

Section: Tart›flmaunclassified

“…'lar› 9 yayg›n lineer porokeratoz tan›s› konulan 50 yafl›nda bir bayan hastaya 30 mg/gün asitretin tedavisi bafllam›fl. Daha önce uygulanan laser dermabrazyon, topikal tretinoin, imiquimod ve tazoroten tedavilerden fayda görmeyen bu hastada bir ay içinde klinik düzelme, 7. ayda ise hem klinik hem de histopatolojik düzelme tespit etmifllerdir 9 . Bizim hastalar›m›zda da asitretin tedavisiyle lezyonlarda belirgin gerileme izlendi.…”

Section: Tart›flmaunclassified

See 2 more Smart Citations

Asitretin Tedavisiyle Düzelen İki Farklı Tipte Porokeratoz Olgusu

Gökdemir¹,

Aktürk²,

Yıldız³

et al. 2011

Turkderm

View full text Add to dashboard Cite

Retinoids

Dawson¹

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Retinoid drugs find major applications in the topical treatment of cutaneous proliferative disorders such as acne, psoriasis, and photoaging and cutaneous cancers such as cutaneous T‐cell lymphoma (CTCL) and Kaposi's sarcoma. Oral retinoids are successfully used to treat nodular/cystic acne, systemic CTCL, and acute promyelocytic leukemia. This overview of available retinoid drugs and those in the preclinical or clinical pipeline covers their development, indications, clinical trial results, adverse effects, and pharmacology/metabolism. Retinoids have been described historically and functionally in the context of interaction with their nuclear receptors—retinoic acid receptors (RARs) and retinoid X receptors (RXRs)—in inducing gene transcription. RAR‐selective retinoids or their prodrugs include first‐generation all‐ trans ‐retinoic acid (tretinoin) and its 13‐ cis isomer (isotretinoin), and second‐generation acitretin and its ethyl ester (etretinate), both having an aromatic 2,3,6‐trimethyl‐4‐methoxyphenyl terminus. Third‐generation more aromatic analogs include ethyl ester tazarotene (Tazorac®) and adapalene (Differin®), both selective for RAR subtypes β and γ, and RARα‐selective pipeline candidates Am80 and NRX 195183, which are in clinical trials. RAR and RXR transcriptional panagonist 9‐ cis ‐retinoic acid is next and is followed by RXR‐selective bexarotene (Targretin™) and two RXR‐selective clinical trial candidates, 9cUAB and NRX 194204. The fourth generation includes three compounds that may have applications in the treatment or prevention of cancer. While originally considered as retinoids, such as N ‐(4‐hydroxyphenyl) retinamide, or as retinoid‐related or derived, such as ST1926 (AHPC) and SHetA2, they subsequently were found to function independently of the RARs and RXRs in inhibiting cancer cell proliferation and inducing apoptosis.

show abstract

Systematized linear porokeratosis: A rare variant of diffuse porokeratosis with good response to systemic acitretin

Cited by 27 publications

References 8 publications

Unilateral generalized linear porokeratosis with nail dystrophy

Unilateral generalized linear porokeratosis with nail dystrophy

Asitretin Tedavisiyle Düzelen İki Farklı Tipte Porokeratoz Olgusu

Retinoids

Contact Info

Product

Resources

About